Modality
siRNA
MOA
CGRPant
Target
TROP-2
Pathway
Ferroptosis
IPFPNH
Development Pipeline
Preclinical
~May 2016
→ ~Aug 2017
Phase 1
~Nov 2017
→ ~Feb 2019
Phase 2
~May 2019
→ ~Aug 2020
Phase 3
Nov 2020
→ Mar 2026
Phase 3Current
NCT03923781
2,467 pts·PNH
2020-11→2026-03·Recruiting
2,467 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-133w agoPh3 Readout· PNH
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
P3
Recruit…
Catalysts
Ph3 Readout
2026-03-13 · 3w ago
PNH
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03923781 | Phase 3 | PNH | Recruiting | 2467 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF |